{"entity":{"id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of CGT4859 in biliary tract cancer, run by Cogent Biosciences, Inc., active and no longer recruiting.","summary":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06777316 by Cogent Biosciences, Inc., with 110 participants enrolled, started 2025-01-22 and due to reach its primary completion in 2027-03. Interventions recorded: CGT4859.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06777316","url":"https://clinicaltrials.gov/study/NCT06777316"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cgt4859"],"companies":["cogent-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06777316","phase":"1/2","setting":"A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations","sponsor":"Cogent Biosciences, Inc.","enrolled":110,"outcomes":[]},"route":"/trials/nct06777316/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"drug":[{"id":"cgt4859","kind":"drug","name":"CGT4859","route":"/drugs/cgt4859/"}],"company":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/"}]}}